Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

Trial Details

NCT ID
NCT05783323
Phase
PHASE2
Sponsor
Children's Hospital of Philadelphia
Status
RECRUITING
Cancer Type
Papillary Thyroid Cancer
Interventions
  • Larotrectinib monotherapy
  • 131I therapy
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Memphis, Tennessee, United States|35.14953,-90.04898
  • Houston, Texas, United States|29.76328,-95.36327
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Age ≥ 1 year
  • Histologic diagnosis of a differentiated thyroid cancer, s/p thyroidectomy and adequate local therapy (e.g., lymph node dissection as per standard …
  • Anatomically evaluable disease on chest CT meeting one of the following criteria (obtained within 90 days of enrollment):
  • A. multiple (\> 10) noncalcified solid pulmonary nodules visible on CT and/or B. enlarging, discrete pulmonary nodules visible on CT of any number …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Papillary Thyroid Cancer Trials on Trialify →